Search Results - andrew+flyak

2 Results

Sort By:

Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for Hepatitic C

Value Proposition· Compositions for inducing anti-HCV immune responses · Nucleoside-modified RNA encoding one or more HCV antigens to induce robust preventive or therapeutic adaptive immune responses against HCV Unmet Need· Hepatitis C virus (HCV) infection remains a significant clinical burden and is the leading cause of liver transplantation...

Published: 7/5/2024 | Inventor(s): Justin Bailey, Stuart Ray, James Crowe, Andrew Flyak, George Shaw, Drew Weissman

Keywords(s):

Category(s): Technology Classifications > Diagnostics

Hepatitis C virus E1E2 genes stimulating development of broadly neutralizing antibodies

Unmet Need185 million people worldwide are infected with Hepatitis C (HCV). It is a major cause of liver failure and hepatocellular carcinoma. Recent development of potent, oral, interferon-free therapies have improved treatment of HCV significantly, but treatment alone is unlikely to eradicate the disease. There remain the issues of therapy being costly,...

Published: 7/4/2024 | Inventor(s): Justin Bailey, James Crowe, Andrew Flyak, George Shaw, Stuart Ray

Keywords(s): Biologics, Disease Indication, Hepatitis C Virus, Hepatitis C Virus (HCV), Infectious Diseases, Therapeutic Matter, Therapeutic Substance, Therapeutics, Vaccine, Viral Infections

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Hepatitis C Virus, Clinical and Disease Specializations > Infectious Diseases > Viral Infections